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Induction of NANOG expression by targeting promoter sequence with small
activating RNA antagonizes retinoic acid-induced differentiation
Xiaoling WANG, Ji WANG, Vera HUANG, Robert F. PLACE and Long-Cheng LI1
Department of Urology, University of California San Francisco, San Francisco, CA 94158, U.S.A. and Helen Diller Family Comprehensive Cancer Center, University of California San
Francisco, San Francisco, CA 94158, U.S.A.
RNAa (RNA activation) is a mechanism by which small dsRNA
(double-stranded RNA), termed saRNA (small activating RNA),
target promoter sequences to induce gene expression. This
technique represents a novel approach to gene overexpression
without the use of exogenous DNA. In the present study, we
investigated whether RNAa can modulate expression of the
development-related gene NANOG and manipulate cell fate.
Using a lentivirus-based reporter system as a screening tool, we
identified synthetic saRNAs that stimulate NANOG expression in
human NCCIT embryonic carcinoma cells. Mismatch mutations
to saRNA duplexes define sequence requirement for gene
activation. Functional analysis of NANOG induction reveals
saRNA treatment predictably modulates the expression of several
known downstream target genes, including FOXH1 (forkhead
box H1), REST (RE1-silencing transcription factor), OCT4
(octamer-binding protein 4) and REX1 (reduced expression
protein 1). Treatment with RA (retinoic acid) triggers NCCIT
cell differentiation, reducing NANOG and OCT4 expression and
up-regulating several neural markers [i.e. ASCL1 (achaete-scute
complex homologue 1), NEUROD1 (neuronal differentiation
1) and PAX6 (paired box 6)]. However, co-treatment with
saRNA antagonizes NANOG down-regulation and RA-induced
differentiation. Ectopic overexpression of NANOG via lentiviral
transduction further recapitulates saRNA results, providing proof-
of-concept that RNAa may be utilized to activate development-
related genes and manipulate cell fate.
Key words: cell fate, differentiation, induced pluripotent stem cell
(iPS cell), NANOG, RNA activation (RNAa).
INTRODUCTION
RNAa (RNA activation) is a newly identified phenomenon of gene
induction triggered by small dsRNAs (double-stranded RNAs)
[1–3]. This class of dsRNA, termed saRNA (small activating
RNA), targets non-coding sequences in gene promoters leading to
changes in chromatin structure and transcriptional activation [1,3–
5]. RNAa is conserved in at least mammalian cells having been
shown to activate a number of genes, including CDKN1A (cyclin-
dependent kinase inhibitor 1A; p21), CDH1 (E-cadherin), PGR
(progesterone receptor), KLF4 (Kru¨ppel-like factor 4), VEGF
(vascular endothelial growth factor), NKX3.1 (NK3 homeobox
1), TP53 (p53) etc. [2,6–8]. As such, saRNAs represent a novel
tool for stimulating endogenous gene expression.
Viral-mediated overexpression systems are widely used to
manipulate cell fate. For instance, ectopic expression of various
defined factors [e.g. OCT4 (octamer-binding protein 4), GATA4
(GATA-binding protein 4)] has been used to generate iPS (induced
pluripotent stem) cells and direct conversion of fibroblasts into
blood progenitor cells or cardiomyocytes [9–11]. However, viral-
based systems have inherent drawbacks that interfere with clinical
application, including adverse effects on the host genome integrity
and immunological consequences. Alternative approaches to gene
overexpression that circumvent such problems may improve
therapeutic development of cell-based technologies.
NANOG is a transcription factor that plays a critical role in
regulating cell fate. In embryonic development, it is involved
in maintaining the pluripotent ICM (inner cell mass), sustaining
the epiblast and preventing cell differentiation [12–15]. NANOG
is also highly expressed in pluripotent cell lines, including ES
(embryonic stem), EG (embryonic germ) and EC (embryonic
carcinoma) cells. However, NANOG levels sharply decline
at the post-implantation stages of embryogenesis and during
differentiation in cell culture [12]. In fact, suppression of NANOG
alone can cause ES cells to differentiate into extra-embryonic
lineages [16,17]. Ectopic expression of NANOG has also been
utilized to maintain pluripotent phenotypes in cultured ES cells.
For instance, NANOG overexpression has been reported to
maintain mouse ES cell pluripotency in the absence of LIF
(leukaemia inhibitory factor) [12], as well as to enable human
ES cells to grow in a feeder-free environment [18]. NANOG is
among the four defined stem cell factors used to reprogram human
fibroblasts into iPS cells [19]. Although NANOG is dispensable in
some instances of iPS reprogramming, it is a stringent selection
marker for germline-competent iPS cells with increased ES cell-
like properties [20]. Currently, almost all methods of NANOG
overexpression require the use of exogenous genetic material (e.g.
viral-based vectors). In the present study, we identify saRNAs
that activate NANOG expression and antagonize RA (retinoic
acid)-induced differentiation of NCCIT cells. Our results provide
Abbreviations used: ASCL1, achaete-scute complex homologue 1; dsRNA, double-stranded RNA; ES, embryonic stem; FOXH1, forkhead box H1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; HEK, human embryonic kidney; Hsp70, heat-shock protein
70; iPS, induced pluripotent stem; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NEUROD1, neuronal
differentiation 1; OCT4, octamer-binding protein 4; PAX6, paired box 6; RA, retinoic acid; REST, RE1-silencing transcription factor; REX1, reduced
expression protein 1; RNAa, RNA activation; RT, reverse transcription; saRNA, small activating RNA; SSEA, stage-specific embryonic antigen; TSS,
transcription start site.
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proof-of-concept that RNAa may provide an alternative approach
to DNA-based overexpression systems for manipulating cell fate.
EXPERIMENTAL
saRNA design
A 1 kb section of the human NANOG promoter sequence was
scanned for saRNA target sites based on rational design rules
as reported previously [1,6]. All of the saRNA sequences
found are listed in Supplementary Table S1 (available at
http://www.BiochemJ.org/bj/443/bj4430821add.htm).
Cell culture and saRNA transfection
NCCIT cells were maintained in RPMI 1640 medium supple-
mented with 10% FBS (fetal bovine serum), 10 mM Hepes,
1 mM sodium pyruvate, 4.5 g/l glucose, 100 units/ml penicillin
and 100 μg/ml streptomycin in a humidified atmosphere of 5%
CO2 maintained at 37 ◦C. Cells were plated in growth medium
without antibiotics at a density of ∼15%. Transfection of saRNAs
was carried out using LipofectamineTM RNAiMax (Invitrogen)
according to the manufacturer’s instructions.
RA-induced differentiation
NCCIT cells were dissociated as single cells and maintained at the
prescribed cell density in standard growth medium supplemented
with 10 μM all-trans-RA (Sigma-Aldrich) for 2 weeks. RA was
stored as a solution (10 mM in DMSO) and diluted in growth
medium as needed. The medium was replenished every 2 days.
mRNA expression analysis
Total RNA was isolated by using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. RNA (1 μg) was
reverse transcribed with oligo(dT) primers. The resulting cDNA
samples were amplified by RT (reverse transcription)–PCR using
gene-specific primer sets in conjunction with the Power SyBr
Green PCR Master Mix (Applied Biosystems). All of the primer
sequences are listed in Supplementary Table S1.
NANOG promoter reporter assay
The pGreen-Zeo-NANOG reporter plasmid was obtained from
System Biosciences. It contained a 2587 bp fragment of the
NANOG promoter (− 2452/ + 135) cloned upstream of the
destabilized GFP (green fluorescent protein) copGFP gene.
Lentiviral particles were generated by transfecting HEK (human
embryonic kidney)-293T cells (Invitrogen) with pGreen-Zeo-
NANOG in conjunction with the packaging plasmids pLP1, pLP2
and pLP/VSVG (Invitrogen) for 48 h. The media were harves-
ted and used to infect NCCIT cells. Transduced cells carrying the
GFP reporter construct were sorted by FACS (UCSF Laboratory
of Cell Analysis, San Francisco, CA, U.S.A.) 3 days after
infection. Cells expressing low-to-moderate basal levels of GFP
were enriched in the sorted cell population in order to improve
the detection of GFP induction. The resulting cells (NCCIT
NANOG–GFP) were subcultured and routinely inspected for
GFP fluorescence by microscopy. GFP expression remained
stable for several months. NCCIT NANOG–GFP cells were
transfected with saRNA for 4 days and subsequently analysed on
a FACSCalibur flow cytometer (Becton Dickinson) for changes in
GFP levels. Forward- and side-scatter plots were used to exclude
dead cells, debris and doublets from the histogram analysis.
The WinMDI program (http://facs.scripps.edu/software.html)
was used to analyse the percentage of GFP positive cells.
Lentivirus-based overexpression of NANOG
A lentiviral human NANOG cDNA overexpression vector
(pSin-EF2-NANOG-Pur) was obtained from Addgene (Addgene
plasmid 16578). Lentiviral particles were generated by
transfecting HEK-293T cells (Invitrogen) with pSin-EF2-
NANOG-Pur in conjunction with the packaging plasmids pLP1,
pLP2 and pLP/VSVG (Invitrogen) for 48 h. The media were
harvested and used to infect NCCIT cells. Puromycin (2 μg/ml)
was used to select transduced cells 3 days after infection.
Immunoblot analysis
Immunoblot analysis was performed according to standard
laboratory protocol as published previously [21,22]. Primary
antibodies included anti-NANOG (1:1000 dilution; 3580S,
Cell Signaling Technology), anti-β-3-tubulin (1:1000 dilution;
ab18207, Abcam) and anti-OCT-3/4 (C-10) (1:1000 dilu-
tion, mouse monoclonal; sc-5279, Santa Cruz Biotechnology)
antibodies. Anti-GAPDH (glyceraldehyde-3-phosphate dehyd-
rogenase) (1:5000 dilution, rabbit monoclonal; #2118, Cell
Signaling Technology), anti-β-actin (1:3000 dilution; AC-15,
Sigma–Aldrich), anti-Hsp70 (heat-shock protein 70) (1:2000 di-
lution; Thermo Fisher Scientific) and anti-α-tubulin (1:5000 dilu-
tion; Sigma–Aldrich) antibodies were used as loading controls.
Cell proliferation assay
Cells were transfected with saRNA and re-seeded into 96-
well plates the next day at a density of 5000 cells/well.
Cell proliferation was measured 4 days later by using the
CellTiter96 Aqueous one solution cell proliferation assay kit
(Promega) containing MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] re-
agent according to the manufacturer’s protocol.
RESULTS AND DISCUSSION
Identification of saRNAs that target the NANOG promoter by
using a GFP reporter system
NANOG expression is silenced in most normal primary and cancer
cells [12]. However, NCCIT (human embryonic carcinoma) cells
are a developmentally pluripotent cell line that express high levels
of stem cell markers, including OCT4, NANOG, SSEA (stage-
specific embryonic antigen)-1, SSEA-3, SSEA-4, TRA-1-81 etc.
[23]. NCCIT cells can also be influenced to differentiate into
derivatives of all three embryonic germ layers (i.e. ectoderm,
mesoderm and endoderm) and extra-embryonic cell lineages
[23,24]. As such, NCCIT cells were selected to determine whether
RNAa can be used to activate NANOG expression in vitro and
influence cell fate.
Selecting saRNA target sites within gene promoters is largely
a hit-or-miss process. Promoter sequence, chromatin structure,
accessibility, overlapping non-coding transcripts etc. may all play
a role in influencing transcription and susceptibility to RNAa
[5,8]. In order to improve screening efficiency, we generated stable
NCCIT (NCCIT NANOG–GFP) cells that contained GFP under
control of the human NANOG promoter by lentiviral transduction.
Measuring GFP intensity would serve as a readout for the
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Figure 1 Identification of NANOG saRNAs using a GFP reporter system
(A) Schematic representation of the NANOG promoter. Indicated are the names of each saRNA and its target site relative to the TSS ( + 1). A SINE (short interspersed element) repetitive element is also
indicated in the NANOG promoter. (B) NCCIT cells were infected with lentiviral particles containing GFP under the control of the human NANOG promoter. At 3 days after transduction GFP-positive
cells (NCCIT NANOG–GFP) were collected by cell sorting and subcultured for saRNA transfection. NCCIT NANOG–GFP cells were transfected with 50 nM concentrations of the indicated saRNAs for
three days and analysed by FACS to assess GFP intensity in each population. Mock samples were transfected in the absence of saRNA. Representative data of n = 2. (C) NCCIT cells were transfected
with the indicated dsRNA at 100 nM. MTT assay was conducted 96 hours following transfection. Results are plotted as the percentage of viable cells relative to mock transfections (means +− S.D. for
two independent experiments).
transcriptional activity of the NANOG promoter. We designed
a series of saRNAs that targeted the NANOG promoter at sites
ranging from − 82 to − 988 relative to the TSS (transcription
start site) by following previously described design rules [6]
(Figure 1A and Supplementary Table S1). Each duplex was
named according to its target within the NANOG promoter
(i.e. dsNanog-82, dsNanog-153, dsNanog-194 etc.). A control
saRNA (dsControl) was also synthesized that lacked significant
homology with all known human sequences. Each saRNA
was transfected into NCCIT NANOG–GFP cells and the GFP
intensity was assessed by flow cytometry. Compared with the
control treatments, dsNanog-82, -205, -752 and -926 caused at
least a 2.7-fold increase in the percentage of the GFP-positive
populations, whereas the other saRNAs did not significantly
alter GFP expression (Figure 1B). To exclude the possibility
that cytotoxic effects may be contributing to the increase in
GFP signal, a MTS assay was conducted on the transfected
cells (Figure 1C). We found that dsNanog-752 had minimal
effects on cell proliferation, whereas dsNanog-82, -205 and -926
similarly inhibited cell growth (Figure 1C). As such, cytotoxic
effects may account for the subtle increase in GFP signal in
dsNanog-82 and dsNanog-205 transfected cells. However, GFP
induction by dsNanog-752 and dsNanog-926, which caused the
highest shift among all NANOG dsRNAs (Figure 1B), may not
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Figure 2 saRNA-mediated NANOG overexpression in human embryonic carcinoma NCCIT cells
(A) NCCIT cells were transfected with 50 nM concentrations of the indicated saRNAs for 96 h. Mock samples were transfected in the absence of saRNA. NANOG expression was assessed by
quantitative RT–PCR. Results are the fold changes relative to mock transfections (means +− S.D. for three independent experiments). *P < 0.05 compared with the mock. (B) NCCIT cells were
transfected with mock, dsControl, dsNanog-752 or dsNanog-926 for 72 h. NANOG protein level was detected by immunoblot analysis. Hsp70 served as a loading control. (C) Representative phase
contrast cell images were taken at 40× magnification 72 h after transfection of the indicated saRNAs. (D) NCCIT cells were transfected with dsNanog-752 for 3 days at concentrations ranging from
10 to 200 nM. Expression of NANOG was assessed by quantitative RT–PCR and normalized to GAPDH. Results are fold changes relative to mock transfections (means +− S.D. for three independent
experiments). (E) NCCIT cells were transfected with 50 nM dsNanog-752 for the indicated lengths of time. The expression of NANOG protein was detected by immunoblot analysis at each time point.
α-Tubulin served as a loading control. Representative blot of n = 2.
result entirely from cytotoxicity, but rather increases in GFP
expression.
saRNA-mediated induction of endogenous NANOG expression in
NCCIT cells
To further validate the screening results, we individually
transfected each saRNA into NCCIT cells and evaluated
endogenous NANOG expression by quantitative RT–PCR.
Compared with the control transfections, dsNanog-752 and
dsNanog-926 caused a 2.87- and 2.97-fold increase in NANOG
mRNA levels respectively (Figure 2A). The remaining duplexes
did not significantly induce NANOG expression. Collectively,
analysis of NANOG expression following saRNA treatment
correlated with the results from the GFP reporter assay.
Immunoblot analysis indicated dsNanog-752 and dsNanog-
926 also increased NANOG protein levels in NCCIT cells
(Figure 2B). Morphologically mock- and dsControl-treated cells
remained healthy, whereas dsNanog-752-transfected cells formed
compact ES-like colonies (Figure 2C). As found when using
the MTS assay, dsNanog-926 caused visible cytotoxic effects
as cells appeared considerably less dense compared with other
treatments (Figures 2C and 1C). Potential off-target effects and/or
stimulation of the innate immune response may contribute to
the cytotoxicity of dsNanog-926 in NCCIT cells. As such, all
subsequent experiments focused on dsNanog-752.
Analysis of mRNA expression also revealed NANOG was
induced in a dose-dependent manner by dsNanog-752 at
concentrations ranging from 10 to ∼50–100 nM, whereas
concentrations higher than ∼50–100 nM did not further increase
NANOG expression (Figure 2D). Time-course experiments
revealed that NANOG protein levels were not induced until
day 3–4, with peak activity around day 5 (Figure 2E). NANOG
levels remained elevated up to day 12. Previous studies have
shown RNAa possesses kinetics distinct from RNAi (RNA
interference) as characterized by an initial ∼48 h delay with
∼10 day continuation in gene activation [1,2,25]. These unique
features of RNAa have been attributed to its nuclear nature and
consequent epigenetic changes at targeted promoters [1,8,25]. Our
observations in the present study reveal that activation NANOG
by dsNanog-752 follows the typical kinetics of RNAa.
Sequence requirement of dsNanog-752 for NANOG induction
To characterize the sequence requirement for dsNanog-752, we
created several mutant saRNAs in which nucleotides at either
the 5′-end (dsNanog-752-5′m-1 and dsNanog-752-5′m-2) or 3′-
end (dsNanog-752-3′m-1 and dsNanog-52-3′m-2) relative with
the antisense strand of dsNanog-752 possessed mismatches
with the targeted promoter sequence (Figure 3A). Analysis
of mRNA expression revealed that dsNanog-752-3′m-1 and
dsNanog-752-3′m-2 possessed activity similar to wild-type
dsNanog-752, whereas dsNanog-752-5′m-1 and dsNanog-752-
5′m-2 were not capable of inducing NANOG expression
(Figure 3B). Immunoblot analysis also confirmed mutant saRNA
RT–PCR results (Figure 3C). These findings indicate that
mutation to the 3′-end of dsNanog-752 does not interfere with
RNAa activity, whereas mutation of the 5′-end abolishes its ability
to activate NANOG expression. Similar to our previous results
evaluating the sequence requirement for RNAa at the E-cadherin
and p21 promoters [1,3], the 5′-end of the antisense strand in
dsNaong-752 is important for RNAa specificity. As such, the
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Figure 3 Sequence requirement for dsNanog-752
(A) Mutations to the 5′-end (relative of the antisense strand) of dsNanog-752 resulted in duplexes dsNanog-752-5′m-1 and dsNanog-752-5′m-2. Mutations to the 3′-end of dsNanog-752 created
mutant derivatives dsNanog-752-3′m-1 and dsNanog-752-3′m-2. The mutated bases are shown in bold. (B) NCCIT cells were transfected with 50 nM of the indicated saRNA molecules for 96 h.
Expression of NANOG was accessed by quantitative RT–PCR and normalized to GAPDH. Results are fold changes relative to mock transfections (means +− S.D. for two independent experiments).
*P < 0.05 compared with the mock. (C) NCCIT cells were transfected as in (B) and NANOG protein levels were detected by immunoblot analysis. α-Tubulin served as a loading control.
antisense strand likely serves as the ‘guide’ strand responsible for
targeting sequence at the NANOG promoter.
NANOG induction by saRNA modulates the expression of its
downstream genes
NANOG is a key transcription factor involved in regulating
embryonic development and self-renewal of pluripotent stem
cells. Using genome-wide location analyses, hundreds of genes
have been identified as downstream targets of NANOG [26–28]. To
determine if RNAa-based overexpression of NANOG influences
downstream gene expression, we evaluated mRNA levels of
several known downstream genes [i.e. OCT4, REX1 (reduced
expression protein 1), REST (RE1-silencing transcription factor)
and FOXH1 (forkhead box H1)] [29,30] following dsNanog-752
transfection in NCCIT cells. As a positive control, NANOG cDNA
was also overexpressed in NCCIT cells using a lentiviral vector
(pSin-Nanog). As expected, ectopic overexpression via pSin-
Nanog elevated NANOG mRNA levels by 8.3-fold and predictably
increased expression of all four downstream genes (Figure 4).
Similarly, albeit to a lesser extent, dsNanog-752 also up-regulated
the expression of each downstream gene (Figure 4). This result
suggests restoration of endogenous NANOG expression by RNAa
results in a functional protein capable of predictably modulating
the expression of its downstream genes.
NANOG activation by saRNA antagonizes RA-induced
differentiation in NCCIT cells
Since exogenous NANOG expression can sustain pluripotency
in ES cells [12,18], it would be interesting to determine if
RNAa-mediated overexpression of NANOG can also prevent
cell differentiation. It has been reported that certain chemical
compounds (e.g. RA) induce neuronal-like features in human
embryonic carcinoma cells [23]. To analyse the effects of
Figure 4 dsNanog-752 induces expression of downstream NANOG-
regulated genes
NCCIT cells were transfected with 50 nM concentrations of the indicated saRNAs for 96 h.
Mock samples were transfected in the absence of saRNA. Expression of NANOG and its
downstream genes (OCT4, REX1, REST and FOXH1) was assessed by quantitative RT–PCR and
normalized to GAPDH. Results are fold changes relative to mock transfections (means +− S.D.
for three independent experiments). *P < 0.05 compared with the mock. cDNA generated from
NCCIT cells transduced with lentivirus (pSin-Nanog) served as a positive control for NANOG
overexpression.
dsNanog-752 on RA-induced differentiation, we treated NCCIT
cells with 10 μM RA for 2 weeks. During this period, the cells
were transfected with dsNanog-752 every 4 days for a total of
12 days. NCCIT cells transduced with pSin-Nanog lentivirus
particles were also treated with RA and served as a positive
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Figure 5 dsNanog-752 maintains an ES-like morphology in NCCIT cells treated with RA
NCCIT cells treated with 10 μM RA were transfected with 50 nM of the indicated dsRNAs every 4 days. Representative phase-contrast cell images were taken at 40× magnification on day 14 after
transfection.
Figure 6 dsNanog-752 antagonizes RA-induced differentiation in NCCIT cells
NCCIT cells were cultured with 10 μM RA and co-treated with 50 nM concentrations of the indicated saRNAs every 96 h for 14 days. NCCIT cells transduced with lentivirus (pSin-Nanog) served
as a positive control for NANOG overexpression. mRNA expression levels of NANOG (A) and OCT4 (B) were assessed by quantitative RT–PCR and normalized to that of GAPDH. Results are fold
changes relative to the 10 μM RA treatment (means +− S.D. for three independent experiments). (C) Protein levels of OCT4 were detected by immunoblot analysis. GAPDH served as a loading
control. Representative blot of n = 2. (D) Neural markers ASCL1, NEUROD1 and PAX6 were assessed by quantitative RT–PCR and normalized to that of GAPDH. Results are fold changes relative
to the 10 μM RA treatment (means +− S.D. for three independent experiments). * P < 0.05 compared with RA. ND, not detectable. (E) Protein levels of β-3-tubulin were detected by immunoblot
analysis. β-actin served as a loading control. Representative blot of n = 2.
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control for NANOG overexpression. Phenotypically, RA forced
mock- and dsControl-treated cells to differentiate as evident
by the loss of compact, ES-like colony structure, whereas
dsNanog-752 and lentiviral Nanog overexpression allowed cells
to retain ES-like colony morphology (Figure 5). Expression
analysis by quantitative RT–PCR revealed RA also caused
a 98.7% decrease in NANOG mRNA levels compared with
the untreated cells; however, dsNanog-752 sustained NANOG
expression in the presence of RA treatment resulting in ∼15.7-
fold higher NANOG mRNA levels compared with dsControl
transfected cells (Figure 6A). Lentiviral transduced cells (pSin-
Nanog) produced ∼1500-fold higher NANOG mRNA levels
compared with dsControl treatments (Figure 6A). Since OCT4
is a key downstream gene of NANOG, we also evaluated its
expression following RA-induced differentiation in NCCIT cells.
As shown in Figures 6(B) and 6(C), expression of OCT4
exhibited a pattern in concordance with NANOG (Figure 6A),
suggesting tight regulation of OCT4 by NANOG in NCCIT cells.
Interestingly, despite differences in magnitude between RNAa-
and lentiviral-mediated overexpression of NANOG in RA-treated
cells (Figure 6A), both techniques maintained similar levels of
OCT4 expression (Figure 6B). It has been proposed that RNAa
may represent a more natural approach to gene overexpression
capable of facilitating similar measurable effects on downstream
phenotypes as ectopic overexpression systems without the need
for massive product output [6].
Consistent with the findings from previous studies [23,31],
RA treatment also up-regulated several markers for neural
differentiation [i.e. ASCL1 (achaete-scute complex homologue
1), NEUROD1 (neuronal differentiation 1) and PAX6 (paired
box 6)], suggesting RA promotes differentiation of NCCIT
cells towards neurons (Figure 6D). However, co-treatment
with dsNanog-752 significantly curbed neural marker gene up-
regulation by RA in a manner similar to pSin-Nanog-transduced
cells (Figure 6D). Although not sufficient to completely halt RA
activity, these results demonstrate that dsNanog-752 antagonized
the differentiation phenotype induced by RA treatment in NCCIT
cells. In support of this, immunoblot analysis revealed dsNanog-
752 also decreased expression of neural differentiation marker
β-3-tubulin (Figure 6E).
Taken together, this study utilizes RNAa as a molecular tool to
enhance expression of NANOG in human NCCIT cells. NANOG
overexpression by dsNanog-752 led to the predictable modulation
of several downstream genes and antagonized RA-induced
differentiation. Furthermore, these results were recapitulated by
vector-mediated overexpression of NANOG. The findings of the
present study provide proof-of-concept that RNAa may provide
an alternative approach to DNA-based overexpression systems
for manipulating cell fate and activating development-related
genes.
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SUPPLEMENTARY ONLINE DATA
Induction of NANOG expression by targeting promoter sequence with small
activating RNA antagonizes retinoic acid-induced differentiation
Xiaoling WANG, Ji WANG, Vera HUANG, Robert F. PLACE and Long-Cheng LI1
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Table S1 Sequences of dsRNA and oligonucleotide primers
The number in the dsRNA name denotes target location relative to the TSS.
(a)
dsRNA name Sequence (5′→3′)
dsNanog-82 Sense, GGUGAUAGAGCCUUCAUUA[dT][dT]
Antisense, UAAUGAAGGCUCUAUCACC[dT][dT]
dsNanog-153 Sense, AGACGGGAUUAACUGAGAA[dT][dT]
Antisense, UUCUCAGUUAAUCCCGUCU[dT][dT]
dsNanog-194 Sense, UGCAGCUACUUUUGCAUUA[dT][dT]
Antisense, UAAUGCAAAAGUAGCUGCA[dT][dT]
dsNanog-205 Sense, CUGGGUUACUCUGCAGCUA[dT][dT]
Antisense, UAGCUGCAGAGUAACCCAG[dT][dT]
dsNanog-302 Sense, CCUGAUUUAAAAGUUGGAA[dT][dT]
Antisense, UUCCAACUUUUAAAUCAGG[dT][dT]
dsNanog-325 Sense, UCCCAUUCCUGUUGAACCA[dT][dT]
Antisense, UGGUUCAACAGGAAUGGGA[dT][dT]
dsNanog-752 Sense, GCCAGAUUUUGAGACACUA[dT][dT]
Antisense, UAGCUGCAGAGUAACCCAG[dT][dT]
dsNanog-926 Sense, GGGAUAGACAAGAAACCAA[dT][dT]
Antisense, UUGGUUUCUUGUCUAUCCC[dT][dT]
dsNanog-988 Sense, CAGACCUGGGAAGAAGCUA[dT][dT]
Antisense, UAGCUUCUUCCCAGGUCUG[dT][dT]
dsControl Sense, ACUACUGAGUGACAGUAGA[dT][dT]
Antisense, UCUACUGUCACUCAGUAGU[dT][dT]
(b)
Primer name Sequence (5′→3′)
NANOG Forward, AAAGAATCTTCACCTATGCC
Reverse, GAAGGAAGAGGAGAGACAGT
FOXH1 Forward, ACCTGCGACATGACAAGCC
Reverse, CTTTCCAGCCCTCGTAGTCTT
REST Forward, GCATAAAGATCTGTGTAGGCAGG
Reverse, TCCTACTTGAAAGGCGTGAGCA
OCT4 Forward, GACAGGGGGAGGGGAGGAGCTAGG
Reverse, CTTCCCTCCAACCAGTTGCCCCAAAC
REX1 Forward, AACGGGCAAAGACAAGACAC
Reverse, GCTGACAGGTTCTATTTCCGC
ASCL1 Forward, CCTGGTGCGAATGGACTTTG
Reverse, CTCAGGTCCCAGTTGCTCTTC
NEUROD1 Forward, GAAGAGGAAGAGGAGGATGACG
Reverse, TGGTGGTGGGTTGGGATAAG
PAX6 Forward, ACCCATTATCCAGATGTGTTTGCCCGAG
Reverse, ATGGTGAAGCTGGGCATAGGCGGCAG
GAPDH Forward, ATCACCATCTTCCAGGAGCGA
Reverse, TTCTCCATGGTGGTGAAGACG
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